Oncotarget

Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 14. https://www.oncotarget.com/archive/v12/i14/ Cover Paper - “Esomeprazole enhances the effect of ionizing radiation to improve tumor control” https://doi.org/10.18632/oncotarget.28008 Research Paper - “Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer” https://doi.org/10.18632/oncotarget.28014 Research Paper - “MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer” https://doi.org/10.18632/oncotarget.28002 Research Paper - “The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma” https://doi.org/10.18632/oncotarget.28013 Research Paper - “Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia” https://doi.org/10.18632/oncotarget.28000 Research Paper - “Prokineticin-1 induces normal lymphangiogenic activity and is involved in lymphangiogenesis and lymph node metastasis in colorectal cancer” https://doi.org/10.18632/oncotarget.28016 Research Paper - “Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase” https://doi.org/10.18632/oncotarget.28009 Review - “Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment” https://doi.org/10.18632/oncotarget.28010 Research Perspective - “Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives” https://doi.org/10.18632/oncotarget.27936 Research Perspective - “A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies” https://doi.org/10.18632/oncotarget.27960 Keywords - mebendazole, pancreatic cancer, esomeprazole, tumor control, MRI, breast cancer, eltrombopag, colorectal cancer, AML, type 2 diabetes, chlorpromazine, immunotherapy, tumors, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The podcast discusses converting breast cancer cell responses from anti-proliferative to apoptotic using ONC201 and TRAIL. It explores the potential of TRAIL to kill cancer cells while sparing normal cells. The combination of ONC201 and rhTRAIL shows promise in reducing tumor growth rate. The podcast also highlights the use of DR5-agonistic antibodies to enhance cell death in cancer cells. Dr. Wafik S. El-Deiry emphasizes the importance of developing novel therapeutic strategies for breast cancer.

Explore the breakthrough of ONC201 in inducing apoptosis in breast cancer cells by boosting TRAIL protein production. Learn about converting anti-proliferative response to apoptotic, utilizing a trail receptor agonist for better outcomes in resistant tumors.

Discover the potential of LAT1 as an anti-cancer target, its role in amino acid transportation, and high expression in human cancers. Explore oncogenic molecular interactions involving CD98LC and CD98HC. Researchers study LAT1 in cancer using NIH 3T3 cell lines, highlighting its potential as a target for anti-cancer therapies.

Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13. https://www.oncotarget.com/archive/v12/i13/ Cover Paper “Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target” https://doi.org/10.18632/oncotarget.27981 News “A new class of radiosensitizers for glioblastoma” https://doi.org/10.18632/oncotarget.27970 (PDF Download) Research Paper “A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection” https://doi.org/10.18632/oncotarget.27982 Research Paper “Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma” https://doi.org/10.18632/oncotarget.27992 Research Paper “Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study” https://doi.org/10.18632/oncotarget.27991 Research Paper “Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells” https://doi.org/10.18632/oncotarget.27989 Research Paper “TERT and its binding protein: overexpression of GABPA/B in high grade gliomas” https://doi.org/10.18632/oncotarget.27985 Review “Cross-talks in colon cancer between RAGE/AGEs axis and in-flammation/immunotherapy” https://doi.org/10.18632/oncotarget.27990 Review “Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors” https://doi.org/10.18632/oncotarget.27988 Research Perspective “Targeting super-enhancers reprograms glioblastoma central carbon metabolism” https://doi.org/10.18632/oncotarget.27938 Editorial Perspective “Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27919 (PDF Download) Editorial “The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance” https://doi.org/10.18632/oncotarget.27967 (PDF Download) Editorial “Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems?” https://doi.org/10.18632/oncotarget.27958 (PDF Download) Keywords - oncogenicity, glioblastoma, head and neck cancer, immunotherapy, tumors, glioma, colon cancer, epigenetics, cancer immunosurveillance, gefitinib, AML, breast cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researchers discuss using combination therapeutics like 6-mercaptopurine and 5-azacitidine to inhibit resistant triple-negative breast cancer cells, addressing the challenges of drug resistance and relapse in TNBC patients. The study focuses on disrupting the transcriptome and epigenome of adaptable cancer cells to prevent recurrence and metastasis in high-risk breast cancers.

In this week's cover paper of Oncotarget (Volume 12, Issue 12), entitled, "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity," researchers used the CRISPR-Cas9 tool to analyze a p53 mutation in triple-negative breast cancer. The researchers from the City University of New York, Columbia University, and Weill Cornell Medical College wrote that both the C-terminal domain (CTD) and oligomerization domain (OD) of mtp53 R273H proteins are intact, and it is not clear if these regions are responsible for chromatin-based DNA replication activities. To examine the ability of mtp53 R273H to influence cell proliferation, DNA replication, and cell cycle progression of breast cancer cells, the researchers used the CRISPR-Cas9 tool to edit the C-terminal regions of the mtp53 gene. “CRISPR-Cas9 sgRNA editing of the C-terminal regions of the endogenous mtp53 gene were carried out so as to delete gene sequences that correspond to the OD and CTD regions.” The team generated breast cancer cells and edited CTD and OD regions of mtp53 R273H using the CRISPR-Cas9 tool. They then treated the cell populations with thymidine—to block cells at G1/S phase in the cell cycle. The researchers then compared the status and proliferation of the variants with the original cell line and observed changes in total cell lysates by western blot analysis. “We examined how changes in the level of mtp53 R273H level and/or deletion of the CTD, or OD plus CTD, region influenced cell proliferation, cell cycle progression, and chromatin association of mtp53, RPA, PCNA and MCM2.” Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27975 DOI - https://doi.org/10.18632/oncotarget.27975 Full text - https://www.oncotarget.com/article/27975/text/ Correspondence to - Jill Bargonetti - bargonetti@genectr.hunter.cuny.edu Keywords - mutant p53, gain-of-function, oligomerization, DNA replication, frame-shift, breast cancer About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12. The full issue of Oncotarget: https://www.oncotarget.com/archive/v12/i12/ COVER PAPER: “Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity” https://doi.org/10.18632/oncotarget.27975 NEWS: “LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma” https://doi.org/10.18632/oncotarget.27968 (PDF Download) EDITORIAL: “Neoantigen evolution in head and neck cancer progression: Where do we go from here?” https://doi.org/10.18632/oncotarget.27942 (PDF Download) EDITORIAL: “Unexpected zinc dependency of ferroptosis – what is in a name?” https://doi.org/10.18632/oncotarget.27951 (PDF Download) RESEARCH PAPER: “Role for Fgr and Numb in retinoic acid-induced differentiation and G0 arrest of non-APL AML cells” https://doi.org/10.18632/oncotarget.27969 RESEARCH PAPER: “Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy” https://doi.org/10.18632/oncotarget.27974 RESEARCH PAPER: “Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type” https://doi.org/10.18632/oncotarget.27978 RESEARCH PAPER: “Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis” https://doi.org/10.18632/oncotarget.27979 Keywords - mutant p53, DNA replication, head and neck cancer, biomarker, ferroptosis, retinoic acid(RA), hypoxia, thymic epithelial tumor, mesothelioma, AML, breast cancer, pancreatic cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researchers discuss the use of urine as a non-invasive method for diagnosing bladder cancer, highlighting the advantages over invasive techniques. They explore the potential of urine proteins as biomarkers for detecting and distinguishing bladder cancer grades and stages, with promising results for IL-1 alpha, IL-1 RA, and IL-8.

Exploring the correlation between CEA levels and clinical outcomes in patients with SCCA, a rare cancer linked to HPV infection. Study of 219 patients at a specialized cancer center reveals potential connection between serum CEA levels and metastatic SCCA.